Fundraising Fox

Imu Biosciences

London, GB · Founded 2019 · 79 employees on LinkedIn · 5 known investors

IMU Biosciences uses a multi-omic platform to measure over 100 million immune data points from a single blood sample, resolving 2,500 immune cell subsets to build a large-scale immune dataset. The company applies this "HD Immunology" approach to develop predictive tools for stem cell and organ transplantation and immuno-oncology, partnering with clinical research groups, pharma, biotech and diagnostics companies.

AI & Machine LearningBiotechHealthtech

Founders & leadership

Imu Biosciences was founded in 2019 by Thomas Hayday PhD, Adam Laing PhD, Mario Cantero MBA, and Adam Laing.

TH
Thomas Hayday PhDCo-founder & Chief Research Officer
AL
Adam Laing PhDCo-founder & Chief Scientific Officer
MC
Mario Cantero MBACo-founder & Chief Operating Officer
ALAdam Laing
Adam LainginCo-Founder, President & CSO
JB
John Baker PhDChief Executive Officer

Investors · 5

ExpaWest Hollywood · $250K – $3M
IQ CapitalLondon · $1M – $40M
Molten VenturesLondon · $2.5M – $63M

Also in the syndicate · 2

MeltwindThe British Business Bank

Funding

SEC filings, press & company announcements

$53M disclosed across 1 round · 2026

Source: company announcements and press reports — follow each round's link for the claim.

In the news

IMU Biosciences Raises Over $53 Million Series A To Advance Immune System Decoding Platformpulse2.com · Jun 2026IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat diseasefinance.yahoo.com · Jun 2026IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat diseasecityam.com · Jun 2026IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat diseasebiotech-now.co.uk · Jun 2026IMU Biosciences Raises Additional Capital; Series A funding Reaches Over $53Mfinsmes.com · Jun 2026FinancialContent - IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat diseasemarkets.financialcontent.com · Jun 2026IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat disease - BioSpacebiospace.com · Jun 2026IMU Biosciences announces oversubscribed financing round, bringing its Series A to over $53M as it accelerates its work to decode the immune system with unprecedented resolution and scale, to transform how we understand, diagnose and treat diseasebusinesswire.com · Jun 2026

Frequently asked questions

What does Imu Biosciences do?
IMU Biosciences uses a multi-omic platform to measure over 100 million immune data points from a single blood sample, resolving 2,500 immune cell subsets to build a large-scale immune dataset. The company applies this "HD Immunology" approach to develop predictive tools for stem cell and organ transplantation and immuno-oncology, partnering with clinical research groups, pharma, biotech and diagnostics companies.
Who founded Imu Biosciences?
Imu Biosciences was founded by Thomas Hayday PhD, Adam Laing PhD, Mario Cantero MBA, Adam Laing in 2019.
Who are Imu Biosciences's investors?
Imu Biosciences's investors include Expa, IQ Capital, Molten Ventures.
How much funding has Imu Biosciences raised?
Imu Biosciences has disclosed $53M raised across 1 round.
Where is Imu Biosciences headquartered?
Imu Biosciences is headquartered in London, GB.